|
SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. |
| |
|
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; Bristol-Myers Squibb/Celgene/Juno; Genentech/Roche; Iksuda Therapeutics; Janssen Scientific Affairs; Kite/Gilead; Merck; Monte Rosa Therapeutics; MorphoSys/Incyte; Novartis; Seagen |
Research Funding - ADC Therapeutics; AstraZeneca; Bristol-Myers Squibb; Genentech; Janssen; Kite/Gilead; MorphoSys/Incyte; Novartis |
| |
|
Consulting or Advisory Role - Blue Cross and Blue Shield of Rhode Island; Genmab; Schrodinger; TG Therapeutics |
Research Funding - Adaptive Biotechnologies; Celldex (Inst); Genentech/Roche (Inst); Genmab (Inst); Precision Biosciences (Inst); Spectrum Pharmaceuticals (Inst); TG Therapeutics (Inst) |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - BeiGene; Boryung; Dong-A Socio; Kyowa Kirin; Roche; Sanofi |
| |
|
Employment - Pusan National University Hospital |
| |
|
No Relationships to Disclose |
| |
|
Employment - Chiang Mai University |
Research Funding - AstraZeneca; MSD; Roche |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Employment - Amgen; Genentech |
| |
|
|
Stock and Other Ownership Interests - Genentech |
Patents, Royalties, Other Intellectual Property - Genentech |
Travel, Accommodations, Expenses - Genentech |
| |
|
Employment - Roche/Genentech |
Stock and Other Ownership Interests - Roche/Genentech |
| |
|
Employment - Roche Canada |
| |
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Genentech/Roche |
| |
|
|
| |
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Roche |
Travel, Accommodations, Expenses - Genentech/Roche |
| |
|
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca; BeiGene; Kite/Gilead; Loxo/Lilly; Novartis; nurix; Roche/Genentech |
Research Funding - Amgen; AstraZeneca; Merck; MustangBio |
Patents, Royalties, Other Intellectual Property - CCR4 CAR T cells for treatment of patients with CCR4 positive cancer.; CD33CAR for treatment of patients with CD33+ acute myeloid leukemia. |
Travel, Accommodations, Expenses - Kite/Gilead; Roche/Genentech |